arrow
Y

Yuichiro Kikawa

Kansai Medical University Hospital
H指数:15
被引数:982

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)

转移性乳腺癌患者关注的生活质量问题:欧洲癌症研究与治疗组织转移性乳腺癌模块(EORTC QLQ-MBR)的第一阶段和第二阶段开发

Breast
IF7.9
2026-09-050
OA
SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy

SERENA-6视觉患者报告结局与安全性:卡米昔司rant用于新发ESR1m晚期乳腺癌的一线内分泌治疗

2026-07-240
OAAI
Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study

奥氮平预防接受剂量密集型AC方案(联合节俭糖皮质激素方案)治疗的乳腺癌患者化疗所致延迟性恶心呕吐的疗效:一项单中心试点研究

2026-04-060
OAAI
Comorbidity, treatment toxicity and satisfaction with cancer care: an international cross-sectional study based on the EORTC PATSAT-C33 and OUT-PATSAT7

共病、治疗毒性和癌症护理满意度:一项基于EORTC PATSAT-C33和OUT-PATSAT7的国际横断面研究

2026-02-130
OAAI
Comparison of hypofractionation and conventional fractionation in postmastectomy radiotherapy after immediate breast reconstruction: a systematic review and meta-analysis of complications

乳腺癌术后即刻乳房重建后,比较加速部分量放疗与常规分割放疗并发症的系统性评价与Meta分析

2025-07-280
OA
Japanese translation of the Functional Assessment of Cancer Therapy-Breast+4 (FACT-B+4) following international guidelines: a verification of linguistic validity

根据国际指南进行的癌症治疗功能评估量表-乳腺癌+4(FACT-B+4)的日语翻译:语言有效性的验证

2025-05-080
OA
An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42

国际IV期实地研究-评估乳腺癌EORTC QLQ-BR42患者生活质量的更新模块的心理计量学特性

BREAST
IF7.9
2025-04-010
OAAI
Validation of the Symptom Illustration Scale within an electronic Patient-Reported Outcomes Monitoring environment for metastatic breast cancer patients undergoing chemotherapy

在接受化疗的转移性乳腺癌患者的电子患者报告结果监测环境中验证症状插图量表

2025-04-010
PRE
Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE)
2024-11-180
PRE
An international field study for the reliability and validity of the EORTC communication questionnaire EORTC QLQ-COMU26
2024-10-100
OAAI
Eribulin versus S-1 as fi rst or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a noninferiority, randomised, controlled, open-label, phase 3 trial
2024-08-010
OAAI
Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial)
2024-06-260
PRE
Identification of prognostic and predictive biomarkers for palbociclib add-on therapy using cancer panel sequencing of cell-free DNA in patients with HR-positive HER2-negative advanced and metastatic breast cancer with fulvestrant resistance
2024-03-220
PRE
Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy

接受化疗的转移性乳腺癌患者的电子患者报告结局监测系统的试点试验

2024-01-045
OA